References
1. Mousavi sm, Pourfeizi A, Dastgiri S. Childhood Cancer in Iran.Journal of pediatric hematology/oncology. 2010;32:376-382.
2. pakpour haji agha a, yekani nejhad ms, khoshnevisan a, nikobakht m, mardani a, kamali ardakani s. Health related quality of life associated factors among patients with brain tumors. journal of ilam university of medical sciences. 2013;21(3):1-11.
3. Wilne S, Koller K, Collier J, Kennedy C, Grundy R, Walker D. The diagnosis of brain tumours in children: a guideline to assist healthcare professionals in the assessment of children who may have a brain tumour.Arch Dis Child. 2010;95(7):534-539.
4. Wilne S, Collier J, Kennedy C, Koller K, Grundy R, Walker D. Presentation of childhood CNS tumours: a systematic review and meta-analysis. Lancet Oncol. 2007;8(8):685-695.
5. Gottardo NG, Gajjar A. Chemotherapy for malignant brain tumors of childhood. J Child Neurol. 2008;23(10):1149-1159.
6. Guerreiro Stucklin AS, Ramaswamy V, Daniels C, Taylor MD. Review of molecular classification and treatment implications of pediatric brain tumors. Curr Opin Pediatr. 2018;30(1):3-9.
7. Mehrazin M, Yavari P. Morphological pattern and frequency of intracranial tumors in children. Child’s Nervous System.2007;23(2):157-162.
8. Wells EM, Packer RJ. Pediatric brain tumors. Continuum (Minneap Minn). 2015;21(2 Neuro-oncology):373-396.
9. Bondy ML, Scheurer ME, Malmer B, et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer.2008;113(7 Suppl):1953-1968.
10. Aghayan Golkashani H, Hatami H, Farzan A, et al. Tumors of the Central Nervous System: An 18-Year Retrospective Review in a Tertiary Pediatric Referral Center. Iran J Child Neurol. 2015;9(3):24-33.
11. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
12. Pollack IF. Pediatric brain tumors. Seminars in Surgical Oncology. 1999;16(2):73-90.
13. Echevarría ME, Fangusaro J, Goldman S. Pediatric central nervous system germ cell tumors: a review. The oncologist.2008;13(6):690-699.
14. Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. Experience with irinotecan for the treatment of malignant glioma.Neuro-oncology. 2009;11(1):80-91.
15. Bouffet E, Capra M, Bartels U. Salvage chemotherapy for metastatic and recurrent ependymoma of childhood. Child’s Nervous System.2009;25(10):1293.
16. Friedman GK, Spiller SE, Harrison DK, Fiveash JB, Reddy AT. Treatment of children with glioblastoma with conformal radiation, temozolomide, and bevacizumab as adjuncts to surgical resection.Journal of pediatric hematology/oncology. 2013;35(3):e123-e126.
17. Wagner L, Turpin B, Nagarajan R, Weiss B, Cripe T, Geller J. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors. Pediatric blood & cancer.2013;60(9):1447-1451.
18. Sun T, Warrington NM, Rubin JB. Why does Jack, and not Jill, break his crown? Sex disparity in brain tumors. Biology of sex differences. 2012;3(1):3.
19. Zaky W, Wellner M, Brown RJ, Blüml S, Finlay JL, Dhall G. Treatment of children with diffuse intrinsic pontine gliomas with chemoradiotherapy followed by a combination of temozolomide, irinotecan, and bevacizumab. Pediatric hematology and oncology.2013;30(7):623-632.
20. Hummel TR, Salloum R, Drissi R, et al. A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas. Journal of neuro-oncology. 2016;127(1):53-61.
21. Zhang G, Huang S, Wang Z. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme. Journal of clinical neuroscience. 2012;19(12):1636-1640.
22. Parekh C, Jubran R, Erdreich-Epstein A, et al. Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.Journal of neuro-oncology. 2011;103(3):673-680.
23. Aguilera D, Mazewski C, Fangusaro J, et al. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. Child’s Nervous System.2013;29(4):589-596.
24. Grill J, Geoerger B, Gesner L, et al. Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study.Neuro-oncology. 2013;15(9):1236-1243.